Menu

1 / 20

Why diagnostic delays cost more than time

#fastcompany2#fastcompany#care#costs#patient
Reading 0:00
15s threshold

advertisement

The Fast Company Impact Council is an invitation-only membership community of top leaders and experts who pay dues for access to peer learning, thought leadership, and more.

BY Kengo Takishima

Listen to this ArticleMore info 0:00 / 0:00

The cost of delayed diagnosis in rare disease is often measured in years. It should also be measured in dollars, clinical capacity, and missed opportunities for better care.

Rare disease affects 1 in 10 Americans, and on average, the diagnostic odyssey for a patient with rare disease costs over $220,000 in avoidable medical fees and lost income. It’s significant time and money that patients and families can’t afford to lose. And it doesn’t end there.

The downstream economic impacts are also costly. Every prolonged diagnosis can trigger a cascade of additional appointments, referrals, and procedures that consume resources. Rounds of tests, specialist bottlenecks, and administrative burden intensify the longer a patient goes without a diagnosis.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.